Search results for "Prothrombin"

showing 9 items of 69 documents

Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myelo…

2009

Abstract Abstract 2803 Poster Board II-779 Background. The rate of asymptomatic amyloidosis (asym-amyloidosis) detected in patients with newly diagnosed multiple myeloma (MM) or smoldering multiple myeloma (SMM) is unknown. This topic is significant because unrecognized AL may be associated with increased mortality may change the patient's management. The objective of the present investigation was to evaluate the number and clinical significance of asym-amyloidosis in MM and SM patients at the time of the diagnostic bone marrow (BM) biopsy for MM. Materials and Methods. The study population was selected from the Mayo Clinic Dysproteinemia database and consisted of consecutive patients with …

amyloidosisProthrombin timemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryAmyloidosisImmunologyCell BiologyHematologymedicine.diseaseBiochemistryAsymptomaticGastroenterologySettore MED/15 - Malattie Del SangueSurgerymedicine.anatomical_structureInternal medicineBiopsymedicineClinical significanceBone marrowmedicine.symptomMyelofibrosisbusinessMultiple myelomaBlood
researchProduct

Staphylococcus aureus alpha-toxin attack on human platelets promotes assembly of the prothrombinase complex.

1990

alpha-Toxin, the major cytolysin of Staphylococcus aureus, promotes blood coagulation by its attack on human platelets (Bhakdi S., Muhly, M., Mannhardt, U., Hugo, F., Klapettek, K., Mueller-Eckhardt, C., and Roka, L. (1988) J. Exp. Med. 168, 527-542). In the present study we demonstrate that toxin attack on gel-filtered human platelets initiates the assembly of prothrombinase complexes at rates up to 10-fold of controls. Treatment of platelets with 0.1 microgram/ml alpha-toxin resulted in generation of 1.4 units of thrombin/10(8) platelets. A similar rate of thrombin generation was noted when platelets were subjected to three cycles of freezing and thawing. However, the alpha-toxin-induced …

biologyFactor XFactor VCell BiologyBiochemistryMolecular biologyMicrobiologychemistry.chemical_compoundThrombinCoagulationchemistryProthrombinasebiology.proteinmedicinePlateletMolecular BiologyStaphylococcus aureus alpha toxinPlatelet factor 4medicine.drugJournal of Biological Chemistry
researchProduct

Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review.

2018

Direct oral anticoagulants (DOACs) are indicated in the treatment and prevention of venous thromboembolism (VTE). However, the use of DOACs in unusual VTE, including cerebral venous thrombosis (CVT) and splanchnic venous thrombosis (SVT), and in patients with biological thrombophilia including minor thrombophilia (Factor V Leiden and prothrombin G20210A), major innate thrombophilia (protein C and S deficiency, and antithrombin) and major acquired thrombophilia (antiphospholipid syndrome [APS]), remains controversial due to the paucity of available data. There are some reports of DOACs use in the initial treatment or long-term maintenance of patients with either CVT or SVT, but their efficac…

medicine.medical_specialtyAdministration Oral030204 cardiovascular system & hematologyThrombophilialaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialAntiphospholipid syndromelawInternal medicinemedicineFactor V LeidenHumansThrombophilia030212 general & internal medicineVenous ThrombosisClinical Trials as Topicbusiness.industryAntithrombinAnticoagulantsHematologymedicine.diseaseAntiphospholipid Syndrome3. Good healthVenous thrombosisTreatment OutcomeOncologyProthrombin G20210AbusinessProtein Cmedicine.drugBlood reviews
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

2020

Background & Aims The prevalence of nonalcoholic steatohepatitis (NASH) associated hepatocellular carcinoma (HCC) is increasing. However, strategies for detection of early-stage HCC in patients with NASH have limitations. We assessed the ability of the GALAD score, which determines risk of HCC based on patient sex; age; and serum levels of α-fetoprotein (AFP), AFP isoform L3 (AFP-L3), and des-gamma-carboxy prothrombin (DCP), to detect HCC in patients with NASH. Methods We performed a case-control study of 125 patients with HCC (20% within Milan Criteria) and 231 patients without HCC (NASH controls) from 8 centers in Germany. We compared the performance of serum AFP, AFP-L3, or DCP vs GALAD …

medicine.medical_specialtyCirrhosisCarcinoma HepatocellularMedizinPilot ProjectsMilan criteriaGastroenterologySensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineBiomarkers TumorHumansProtein PrecursorsneoplasmsHepatologyReceiver operating characteristicbusiness.industryLiver NeoplasmsGastroenterologyArea under the curvemedicine.diseasedigestive system diseasesROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaCase-Control StudiesCohort030211 gastroenterology & hepatologyProthrombinalpha-FetoproteinsbusinessLiver cancerBiomarkersCohort study
researchProduct

Octaplex in routine clinical use for prophylaxis and therapy of bleeding in patients with prothrombin complex factor deficiency

2007

Octaplex is a new prothrombin complex concentrate that is indicated for treatment or perioperative prophylaxis of bleeding in patients with deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists or by liver failure, when rapid correction of bleeding is required. The study was conducted to demonstrate both prevention of bleeding and achievement of haemostasis in acute bleeding and to obtain further information about the safety of administration of Octaplex.

medicine.medical_specialtyPediatricsbusiness.industryLiver failurePerioperativeAcute bleedingVitamin kCritical Care and Intensive Care MedicineProthrombin complex concentrateGastroenterologyCoagulationInternal medicinePoster PresentationmedicineIn patientbusinessPROTHROMBIN COMPLEXmedicine.drugCritical Care
researchProduct

Comparación de las frecuencias de los alelos factor V Leiden (G1691A) y protrombina-G20210A entre pacientes con trombosis venosa profunda y población…

2006

Background: Factor V leiden and the -G20210A variant of prothrombin gene are associated to a higher risk of deep venous thrombosis. Aim: To assess the frequency of factor V Leiden (G1691A) and prothrombin -G20210A alleles in patients with deep venous thrombosis (DVT) and in the general population from Spain. Material and methods: Factor V Leiden (g1691a) and prothrombin-g20210a alleles were genotyped in 493 individuals from the Spanish general populations and in 131 patients with DVT. The presence of DVT was confirmed by phlebography. Allelic frequencies and the DVT risk associated with these variants were estimated. Results: Allelic frequencies for the factor V Leiden (G1691A) allele were …

medicine.medical_specialtyPopulationGastroenterologyInternal medicinehemic and lymphatic diseasesGenotypeG20210AVenous thrombosismedicineFactor V Leidencardiovascular diseasesAlleleeducationAlleleseducation.field_of_studyFactor V Leidenbusiness.industryGeneral MedicineOdds ratiomedicine.diseaseConfidence intervalSurgeryVenous thrombosisProthrombin geneProthrombin G20210Abusiness
researchProduct

Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1 + 2 and thrombin-an…

1993

To evaluate the influence of different blood sampling techniques on test results of thrombin-antithrombin III complex (TAT) and prothrombin fragment 1 + 2 (F1 + 2) serial determinations were performed. In six groups of nonrandomized patients (ten patients each) the concentrations of the coagulation markers of blood samples from central catheters (internal jugular, caval, Shaldon, pulmonary artery) and peripheral cannulas (17G and 18G) were compared with those of blood samples obtained simultaneously from direct venipunctures of the contralateral arm. Medians and 25th-75th percentiles of TAT and F1 + 2 concentrations of plasmas obtained from central catheters were not different from those ta…

medicine.medical_specialtymedicine.drug_classAntithrombin IIICatheterizationInternal medicinemedicine.arterymedicineHumansProtein PrecursorsVeinBloodlettingHematologyVenipuncturebusiness.industryPROTHROMBIN FRAGMENT 1.2AnticoagulantHematologyGeneral MedicinePeptide FragmentsCatheterBloodmedicine.anatomical_structureAnesthesiaPulmonary arteryProthrombinbusinessPeptide HydrolasesBlood samplingAnnals of Hematology
researchProduct

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

2018

BACKGROUND AND PURPOSE Whereas intravenous thrombolysis (IVT) is allowed for acute ischaemic stroke in patients on vitamin K antagonists with international normalized ratio ≤1.7, there are no similar recommendations for patients on direct oral anticoagulants (DOACs), notably due to the lack of coagulation tests to assess the therapeutic effects. Although the literature is scarce, consisting of small case series and retrospective studies, considering the frequency of this situation the French Vascular Neurology Society and the French Study Group on Haemostasis and Thrombosis have worked on a joint position paper to provide a practical position regarding the emergency management of ischaemic …

medicine.medical_specialtymedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyAntithrombinsDabigatranBrain Ischemia03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanAtrial FibrillationCoagulation testingMedicineHumansThrombolytic TherapyStrokeRetrospective StudiesProthrombin timeRivaroxabanmedicine.diagnostic_testbusiness.industryAnticoagulantsIdarucizumabThrombolysismedicine.diseaseDabigatranStrokeNeurologyEmergency medicineAdministration IntravenousNeurology (clinical)Blood Coagulation Testsbusiness030217 neurology & neurosurgeryPartial thromboplastin timemedicine.drugFactor Xa InhibitorsEuropean journal of neurology
researchProduct